Pulmonary Endpoints in Duchenne Muscular Dystrophy. A Workshop Summary

Area of Science:

• Pulmonary medicine
• Neuromuscular disorders
• Clinical trial design

Background:

• Duchenne muscular dystrophy (DMD) is a progressive genetic disorder affecting muscle strength, including respiratory muscles.
• Novel therapeutics for DMD are advancing, necessitating standardized methods for assessing respiratory function in clinical trials.
• Nonambulatory subjects with DMD require specific pulmonary assessments to monitor disease progression and treatment efficacy.

Purpose of the Study:

• To summarize existing respiratory data in Duchenne muscular dystrophy.
• To provide guidance for clinical researchers on assessing pulmonary outcomes in DMD clinical trials.
• To establish best practices for evaluating respiratory muscle status in DMD patients, particularly those who are nonambulatory.

Main Methods:

• A workshop was convened by Parent Project Muscular Dystrophy (PPMD) on April 14-15, 2016.
• Published respiratory data in DMD was reviewed and summarized.
• Discussions were held to formulate guidance for clinical researchers.

Main Results:

• The workshop successfully summarized current knowledge on respiratory status in DMD.
• Guidance was developed for assessing pulmonary endpoints in DMD clinical trials.
• Emphasis was placed on methods suitable for nonambulatory individuals.

Conclusions:

• Standardized assessment of pulmonary function is crucial for evaluating novel DMD therapeutics.
• The workshop provided a framework for consistent and effective respiratory outcome measurement in DMD research.
• Further research and consensus are needed to optimize pulmonary endpoint selection in DMD clinical trials.